Cargando…

Association Between PDL1 Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study

BACKGROUND: This study aimed to explore associations between PDL1 polymorphisms and efficacy of apatinib for patients with previously treated advanced non–small cell lung cancer (NSCLC) in a real-world setting. METHODS: We retrospectively recruited 148 patients with previously treated advanced NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Wenxia, Li, Bin, Geng, Nan, He, Xin, Ge, Hui, Wang, Ping, Ding, Cuimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232958/ https://www.ncbi.nlm.nih.gov/pubmed/34188525 http://dx.doi.org/10.2147/IJGM.S303717

Ejemplares similares

The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen
por: Geng, Nan, et al.
Publicado: (2021)

Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study
por: Gou, Miaomiao, et al.
Publicado: (2018)

Real‐world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice
por: Singal, Amit G., et al.
Publicado: (2022)

Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study
por: Li, Li-Hua, et al.
Publicado: (2022)

Tumor-associated eosinophilia in a patient with EGFR-positive, MET-amplified lung adenocarcinoma refractory to targeted therapy: a case report and review of literature
por: Geng, Nan, et al.
Publicado: (2021)

Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC
por: Hu, Rong, et al.
Publicado: (2020)

Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study
por: Lin, Haimin, et al.
Publicado: (2019)

A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data
por: Hinata, Nobuyuki, et al.
Publicado: (2020)

Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study
por: Zhang, Song, et al.
Publicado: (2022)

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data
por: Terai, Hideki, et al.
Publicado: (2022)

Study protocol: A single‐arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first‐line immunotherapy
por: Xing, Puyuan, et al.
Publicado: (2021)

Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study
por: Waddell, T., et al.
Publicado: (2022)

Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study
por: Zhu, Anjie, et al.
Publicado: (2019)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
por: Gong, Taojun, et al.
Publicado: (2022)

Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study
por: Zheng, Zhuangzhuang, et al.
Publicado: (2022)

Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study
por: Tang, Jing, et al.
Publicado: (2019)

Efficacy and Safety of Regorafenib Monotherapy among Patients with Previously Treated Metastatic Colorectal Cancer in a Chinese Population: A Real-World Exploratory Study
por: Wang, Rui-Tao, et al.
Publicado: (2021)

Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices
por: Liu, Stephen V., et al.
Publicado: (2022)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
por: Zhou, Ling, et al.
Publicado: (2023)

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
por: Pan, Dengdeng, et al.
Publicado: (2022)

Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study
por: Zhang, Yong, et al.
Publicado: (2017)

Significant efficacy and well safety of apatinib combined with radiotherapy in NSCLC: Case report
por: Zhao, Chunbo, et al.
Publicado: (2017)

Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report
por: Jin, Jun, et al.
Publicado: (2019)

Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies
por: Li, Haosheng, et al.
Publicado: (2022)

Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study
por: Geng, Qian, et al.
Publicado: (2020)

Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario
por: Flores Vega, Yoanna I., et al.
Publicado: (2023)

Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study
por: Liang, Jianmiao, et al.
Publicado: (2020)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort
por: Gibson, Amanda J. W., et al.
Publicado: (2022)

Real-World Treatment Patterns and Outcomes Among Patients With Metastatic NSCLC Previously Treated With Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors
por: Bains, Savreet, et al.
Publicado: (2022)

Effectiveness and safety of low‐dose apatinib in advanced gastric cancer: A real‐world study
por: Du, Yingying, et al.
Publicado: (2020)

Synthesis of Novel Peptide Dendrimers PDL-GB2 and PDL-G2
por: Yunzhu, Lin, et al.
Publicado: (2015)

Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC: A case report
por: Wu, Yuan-Peng, et al.
Publicado: (2019)

Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases
por: Xu, Jianping, et al.
Publicado: (2020)

Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure
por: Harada, Guilherme, et al.
Publicado: (2019)

Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report
por: Zhao, Yuanyang, et al.
Publicado: (2021)

Real‐world data on eslicarbazepine acetate as add‐on to antiepileptic monotherapy
por: Holtkamp, M., et al.
Publicado: (2016)

Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study
por: Xiao, Yan, et al.
Publicado: (2019)

An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study
por: Li, Ning, et al.
Publicado: (2020)

Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
por: Velcheti, Vamsidhar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0se2afdj2linmlet1qpvk5jkq3